Table 4 Univariate and multivariate analysis of independent predictors for treatment success

Age

 < 35 years

72 (85.7)

–

–

–

–

 35–60 years

73 (73.0)

0.45 (0.2–1.0)

0.04

2.7 (0.6–11.4)

0.2

 ≥ 60 years

14 (77.8)

0.6 (0.16–2.1)

0.6

1.0 (0.3–3.6)

1.0

Type of drug resistance

–

–

 RR

5 (62.5)

–

–

–

–

 MDR

116 (76.3)

0.83 (0.2–3.8)

0.8

–

–

 XDR

36 (58.1)

2.7 (0.6–11.9)

0.2

–

–

Gender (male/female)

114 (77.0)/42 (79.2)

0.9 (0.4–1.9)

0.8

–

–

History of TB treatment (new/previously treated)

16 (84.2)/141 (77.0)

1.6 (0.4–5.7)

0.5

–

–

Cavitary disease at baseline (yes/no)

114 (81.4)/39 (72.2)

0.6 (0.3–1.2)

0.2

–

–

Concomitant diabetes (yes/no)

21 (72.4)/136 (78.6)

1.4 (0.6–3.4)

0.5

–

–

Treatment regimen (bedaquiline/non-bedaquiline)

94 (92.2)/63 (63.0)

6.9 (3.0–15.8)

< 0.001*

7.4 (2.9–18.5)

< 0.001*

Regimen containing (BDQ+ Cfz)/Cfz

87 (94.6)/29(58.0)

12.6 (4.4– 36.4)

<0.001*

13.0 (4.4 –38.1)

< 0.001*

Regimen containing (BDQ+ Lzd)/Lzd

85 (92.4)/13 (56.5)

9.3(3.0 –28.9)

<0.001*

13.7 (1.8–103.8)

0.01*

Regimen containing (BDQ+ FQs)/FQs

19 (82.6)/45(57.7)

3.5 (1.1–11.2 )

0.03*

2.5 (0.5–12.6 )

0.27

Regimen containing (BDQ+Cs)/Cs

71(92.2)/58 (63.7)

6.7 (2.6–17.2)

< 0.001*

13.1 (3.7–45.7)

< 0.001*

BDQ+injectable agents/injectable agents

52 (96.3/60) (65.9)

13.4 (3.1–58.9)

< 0.001*

12.1 (2.7–53.7)

0.001*

BDQ + Lzd+ FQs/Lzd+FQs

14 (82.4)/9 (50.0)

4.7 (0.1–22.0)

0.08

15.2 (1.42–163.3)

0.03*

BDQ+ Lzd+ FQs+ Cfz/Cfz+ Lzd+ FQs

15 (88.2)/3 (33.3)

15.0 (2.0–113.6)

0.01*

38.9 (1.9–817.1)

0.02*